Surfactant therapy for COVID-19 related ARDS: a retrospective case-control pilot study.
Simone PivaRobert M DiBlasiApril E SleeAlan H JobeAldo M RoccaroMatteo FilippiniNicola LatronicoMichele BertoniJohn C MarshallMichael A PortmanPublished in: Respiratory research (2021)
Surfactant delivery through bronchoscopy at a dose of 720 mg in 150 ml normal saline is feasible and safe for COVID-19 ARDS patients and health care providers during the pandemic. Surfactant administration did not cause acute decompensation, may reduce mortality and mechanical ventilation duration in COVID-19 ARDS patients. This study supports the future performance of randomized clinical trials evaluating the efficacy of meticulous sub-bronchial lavage with surfactant as treatment for patients with COVID-19 ARDS.
Keyphrases
- mechanical ventilation
- acute respiratory distress syndrome
- coronavirus disease
- sars cov
- end stage renal disease
- extracorporeal membrane oxygenation
- healthcare
- newly diagnosed
- ejection fraction
- intensive care unit
- respiratory failure
- chronic kidney disease
- prognostic factors
- case control
- coronary artery disease
- cardiovascular events
- risk factors
- drug induced
- smoking cessation